$2.07 Earnings Per Share Expected for Pfizer Inc. (NYSE:PFE) This Quarter

Brokerages predict that Pfizer Inc. (NYSE:PFEGet Rating) will announce earnings of $2.07 per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Pfizer’s earnings, with the lowest EPS estimate coming in at $1.54 and the highest estimate coming in at $2.59. Pfizer posted earnings per share of $1.07 in the same quarter last year, which would indicate a positive year-over-year growth rate of 93.5%. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Pfizer will report full year earnings of $6.61 per share for the current financial year, with EPS estimates ranging from $6.37 to $7.31. For the next financial year, analysts anticipate that the company will report earnings of $5.14 per share, with EPS estimates ranging from $4.20 to $5.63. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Pfizer.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.80 by ($0.18). Pfizer had a return on equity of 39.33% and a net margin of 26.97%. The firm had revenue of $25.66 billion for the quarter, compared to analyst estimates of $24.73 billion. During the same quarter in the previous year, the company earned $0.93 earnings per share. The company’s quarterly revenue was up 76.8% on a year-over-year basis.

Several equities analysts have recently issued reports on the company. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Berenberg Bank set a $50.00 target price on shares of Pfizer in a report on Thursday, April 21st. BMO Capital Markets increased their target price on shares of Pfizer from $60.00 to $76.00 in a report on Friday, January 14th. Citigroup upped their price objective on shares of Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 5th. Finally, Morgan Stanley began coverage on shares of Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 target price on the stock. Eleven analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $57.05.

In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at $1,907,300. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.05% of the company’s stock.

Several large investors have recently modified their holdings of PFE. MJP Associates Inc. ADV raised its stake in shares of Pfizer by 18.9% in the fourth quarter. MJP Associates Inc. ADV now owns 19,458 shares of the biopharmaceutical company’s stock worth $1,102,000 after purchasing an additional 3,096 shares during the last quarter. Harrison & Co Wealth Management LLC bought a new stake in Pfizer during the fourth quarter worth $1,455,000. Capital Advisors Inc. OK boosted its holdings in Pfizer by 3.9% during the 4th quarter. Capital Advisors Inc. OK now owns 541,381 shares of the biopharmaceutical company’s stock worth $31,969,000 after acquiring an additional 20,514 shares during the last quarter. Tobam boosted its holdings in Pfizer by 132.9% during the 3rd quarter. Tobam now owns 45,875 shares of the biopharmaceutical company’s stock worth $1,973,000 after acquiring an additional 26,174 shares during the last quarter. Finally, Parsec Financial Management Inc. boosted its holdings in Pfizer by 90.9% during the 3rd quarter. Parsec Financial Management Inc. now owns 56,207 shares of the biopharmaceutical company’s stock worth $2,659,000 after acquiring an additional 26,762 shares during the last quarter. 66.50% of the stock is currently owned by institutional investors.

PFE traded down $0.47 during trading on Friday, hitting $49.92. 22,423,685 shares of the stock traded hands, compared to its average volume of 24,886,970. Pfizer has a twelve month low of $38.47 and a twelve month high of $61.71. The company has a market cap of $281.94 billion, a price-to-earnings ratio of 11.45, a PEG ratio of 0.59 and a beta of 0.76. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.40 and a quick ratio of 1.19. The business has a 50 day moving average price of $51.27 and a 200 day moving average price of $51.84.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Friday, May 13th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Thursday, May 12th. Pfizer’s payout ratio is 36.70%.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.